Health Care • Biotechnology: Pharmaceutical Preparations
$17.04 ▲ +0.06
(+0.35%)
MKT CAP: $3.18B • VOL: 1.43M
52W L $14 52W H $27
ROARABLE / RQD
D- • 40/100
PIOTROSKI
1 / 9
DYN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$468.2M | -$343.9M | -$242.2M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$446 | -$317 | -$236 |
| EBITDA (Normalized) | -$466.6M | -$342.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$403.2M | -$292.4M | -$188.2M |
| Capital Expenditures (CapEx) | $1.9M | $2.4M | — |
| Free Cash Flow (FCF) | -$405.1M | -$294.7M | -$188.2M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $893.4M | $435.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $972.1M | $629.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DYN.